Case study: the changing IV drug use problem/pattern and what that means to the epidemic
|
|
- Harold Carpenter
- 5 years ago
- Views:
Transcription
1 Case study: the changing IV drug use problem/pattern and what that means to the epidemic Mojca Maticic Faculty of Medicine, University of Ljubljana University Medical Centre Ljubljana Slovenia 4th CEE Meeting HCV/HIV: Prague 2018
2 Disclosure Within the last 36 months: Lecturer: Abbvie, Bayer, Merck, Sandoz Manuscript preparation: Abbvie, Gilead, Merck Travel/accommodational meeting expences: Abbvie, Gilead, Merck No conflict of interest regarding this presentation
3 Hepatitis C: The first ever curable chronic viral infection in medical history
4 Hepatitis C: The first ever curable chronic viral infection in medical history Though curable, HCV continues to have a large human, social and economic impact
5 Global number of deaths continues to rise >400,000 people die each year from HCV-related liver diseases even though HCV is curable >45 deaths every hour >1,095 deaths every day The Boston Consulting Group. Road to Elimination: Barriers and Best Practices in Hepatitis C Management. July 2017.
6 The natural course of HCV infection with no treatment: It takes >20 years of infection to develop life-threatening conditions years + more will die of extrahepatic manifestations For every 100 people infected will develop chronic infection will develop chronic liver disease 5-20 will develop cirrhosis 1-5 will die of cirrhosis or HCC
7 Deaths due to HCV-related hepatocellular carcinoma (%) Deaths due to life-threatening conditions of chronic HCV infection after 20-years of follow up Deaths due to HCV-related extrahepatic manifestations (%) NOT cured NOT cured Cured Cured Lee MH et al. J Infect Dis 2012; 2016:
8 Total Viremic Infected (2016) Age distribution of HCV-infected persons in EU in , , , , , , , , ,000 50,000 - Average age: 54 years The population of HCV-infected has been ageing reaching a critical period for life-threatening conditions to develop Polaris Observatory. Accesses at:
9 PWUD are the driving force of HCV epidemic 80% 60% of new HCV infections of existing HCV infections The Boston Consulting Group. Road to Elimination: Barriers and Best Practices in Hepatitis C Management. July Accessed 5 July 2018 World Hepatitis Alliance. Available at:
10 Estimated prevalence of injecting drug users by country 15.6 million PWID globally (0.33% of those aged years) Degenhardt L et al. Lancet Global Health 2017; 5(12):
11 Estimated prevalence of injecting drug use by country Europe 15.6 million PWID globally (0.33% of those aged years) PWUD Prevalence PWUD N Western 0.34 % 1 million Eastern 1.3 % 3 million Degenhardt L et al. Lancet Global Health 2017; 5(12):
12 Estimated prevalence of injecting drug use by country Europe 15.6 million PWID globally (0.33% of those aged years) PWUD Prevalence PWUD N Western 0.34 % 1 million Eastern 1.3 % 3 million Europe Age >25 y Inject opioids Western 70% 78.3 % Eastern 58% 70% Degenhardt L et al. Lancet Global Health 2017; 5(12):
13 Estimated anti-hcv prevalence among PWUD by country 15.6 million PWID globally 52.3% anti-hcv positive (= 8.2 million) Degenhardt L et al. Lancet Global Health 2017; 5(12):
14 Estimated anti-hcv prevalence among PWUD by country 15.6 million PWID globally 52.3% anti-hcv positive (= 8.2 million) Europe Anti-HCV+ prevalence Anti-HCV+ N Western 53 % 0.5 million Eastern 65 % 1.9 million Degenhardt L et al. Lancet Global Health 2017; 5(12):
15 Anti-HCV seroprevalence among PWUD in Europe EMCDDA European Drug Report : Trends and Developments.
16 What is killing PWID with HCV infection?? Grebely J et al.semin in Liver Dis 2011;31:331-9.
17 HCV treatment with DAAs EASL 2018 Guidelines
18 The solution: continuum of services and a cascade-of-care for HCV management WHO Global hepatitis report, Available at:
19 HCV cascade-of-care in PWUD Grebely J, Hajarizadeh B, Dore GJ. Nat Rev Gastroenterol Hepatol 2017; 14: Iversen J et al. Int J Drug Pol2017.; 42: 1-6.
20 Barriers to HCV treatment access in PWUD PRACTITIONER POLICY Lazarus JV, et al. BMC Infect Dis 2014;14(Suppl 6):S16; Grebely J, et al. J Infect Dis 2013;207:S19 25; Harris M, Rhodes T. Harm Reduct J 2013;10:7; Papatheodoridis GV, et al. Liver Int 2014;34:
21 Restrictions on access to HCV treatment with DAAs include PWUD in several European countries (N=27) European Liver Patients Association. The 2016 Hep-CORE Report. Brussels: ELPA, 2017.
22 Barriers to HCV treatment access in PWUD Barriers need to be adressed and solutions need to be found PRACTITIONER POLICY A fundamental dilema: PWUD are difficult to engage in formal healthcare services Lazarus JV, et al. BMC Infect Dis 2014;14(Suppl 6):S16; Grebely J, et al. J Infect Dis 2013;207:S19 25; Harris M, Rhodes T. Harm Reduct J 2013;10:7; Papatheodoridis GV, et al. Liver Int 2014;34:
23 A Case study male born in : started iv heroin living with his parents unfinished highschool unemployed (precarious) 1999: entered OST programme (methadone 120 ml qid) tested anti-hcv positive, HCV RNA positive in SLOVENIA
24 A Case study male born in : started iv heroin living with his parents unfinished highschool unemployed (precarious) 1999: entered OST programme (methadone 120 ml qid) tested anti-hcv positive, HCV RNA positive in SLOVENIA
25 A Case study male born in : started iv heroin living with his parents unfinished highschool unemployed (precarious) 1999: entered OST programme (methadone 120 ml qid) tested anti-hcv positive, HCV RNA positive in SLOVENIA
26 A Case study male born in : started iv heroin living with his parents unfinished highschool unemployed (precarious) 1999: entered OST programme (methadone 120 ml qid) tested anti-hcv positive, HCV RNA positive in SLOVENIA
27 SLOVENIA Anti-HCV positive persons by risk groups ( ) Inhabitants: 2 million 27% 62% Anti-HCV prevalence HCV RNA prevalence N PWUD 0.4% 0.3% % Alfaleh FZ, Nugrahini N, Maticic M, et al. J Viral Hep 2015; 22: Gregorčič S et al. 3rd CEE Conference on viral hepatitis and HIV, Poster #13.
28 SLOVENIA 20 years of policy for HCV management Matičič M et al. Isis 1999; 8: Matičič M, Kastelic A. Zdrav Vestn 2009; 78: Matičič M, Poljak M. Zdrav Vestn 2010: National Viral Hepatitis Expert Group. Consensus guidelines for DAA treatment. Ljubljana, December 6, 2017.
29 SLOVENIA HCV treatment policy National Health Insurance System: treatment for everybody - Nominated specialists (infectologists, hepatologists) - National guidelines Five centers for HCV treatment Historically all the SOC available Direct Acting Antivirals available Indications: 2015/16: F>2 2017: F : NO restrictions PWUD: Never contraindicated Matičič M et al. Isis 1999; 8: Matičič M, Kastelic A. Zdrav Vestn 2009; 78: Matičič M, Poljak M. Zdrav Vestn 2010: National Viral Hepatitis Expert Group. Consensus guidelines for DAA treatment. Ljubljana, December 6, 2017.
30 SLOVENIA HCV micro-elimination in 2018: It became feasible in certain high-risk populations Lazarus JV et al. J Hepatol. 2017;67: Maticic M et al. EASL ILC Poster #THU-126.
31 Percentage of high-risk opioid users receiving drug treatment in European countries EMCDDA European Drug Report : Trends and Developments.
32 Percentage of high-risk opioid users receiving drug treatment in European countries EMCDDA European Drug Report : Trends and Developments.
33 SLOVENIA 18 Centers for treatment and prevention of drug addiction NIJZ. National Drug Report
34 SLOVENIA 18 Centers for treatment and prevention of drug addiction NIJZ. National Drug Report
35 SLOVENIA National healthcare network for HCV management in PWUD INTEGRATED : 18 Centers for treatment and prevention of of drug addiction 5 Centers for treatment of viral hepatitis Maticic M, Kastelic A. Zdrav Vestn 2009; 78: Maticic M et al. BMC Infect Dis 2014; 14(Suppl 6): 12-3.
36 SLOVENIA since 2007 An integrated care for HCV treatment n in PWUD involving a multidisciplinary team Councilors: -specially trained nurses Social workers Peers Psychiatrist / psychotherapist Viral hepatitis specialist: Infectologists hepatologists HCV Testing & Treatment & Prevention Other support system: -family -friends -co-workers DT specialists Clinical virologiost Clinical pharmacist Maticic M, Kastelic A. Zdrav Vestn 2009; 78: Maticic M et al. BMC Infect Dis 2014; 14(Suppl 6): 12-3.
37 SLOVENIA National healthcare network for managing HCV in PWUD An integrated approach Maticic M, Kastelic A. Zdrav Vestn 2009; 78: Maticic M et al. BMC Infect Dis 2014; 14(Suppl 6): 12-3.
38 SLOVENIA National healthcare network for HCV management in PWUD INTEGRATED : 18 Centers for treatment of drug addiction 5 Centers for treatment of viral hepatitis Maticic M, Kastelic A. Zdrav Vestn 2009; 78: Maticic M et al. Suchtmed : 245. Maticic M et al. BMC Infect Dis 2014; 14(Suppl 6): 12-3.
39 The impact of DAA treatment on prevalence among PWUD a modeling study towards HCV elimination ( ) Frasier H et al. J Hpatol 2018; 68(3):
40 A Case study Male, born in 1971, living with his parents, unfinished highschool, unemployed (precarious) 1991: started iv heroin 1999: entered OST programme (methadone 120 ml qid) tested anti-hcv positive, HCV RNA positive vaccinated for hepatitis B motivated for referral to infectologist refuses 2001: referred to infectologist (still in OST programme) fatigue HCV: GT3, ALT 3xUNL, IU/mL HCV RNA, liver US normal liver biopsy suggested refuses further referals NO HEALTH PROBLEMS ; does not want to have biopsy! 2004: referred to infectologist (still in OST programme) fatigue HCV: ALT 2xUNL, IU/mL HCV RNA PegIFN/RBV suggested (without liver biopsy) refuses further referals NO HEALTH PROBLEMS ; does not want to have treatment side effects! I am fine! Absoultely NO health problems!
41 A Case study Male, born in 1971, living with his parents, unfinished highschool, unemployed (precarious) 1991: started iv heroin 1999: entered OST programme (methadone 120 ml qid) tested anti-hcv positive, HCV RNA positive vaccinated for hepatitis B motivated for referral to infectologist refuses NO HEALTH PROBLEMS 2001: refered to infectologist (still in OST programme) mild fatigue HCV: GT3, ALT 3xUNL, IU/mL HCV RNA, liver US normal liver biopsy suggested refuses further referals 2004: referred to infectologist (still in OST programme) fatigue HCV: ALT 2xUNL, IU/mL HCV RNA PegIFN/RBV suggested (without liver biopsy) refuses further referals NO HEALTH PROBLEMS ; does not want to have treatment side effects! I have NO health problems! Do NOT want any biopsy!
42 A Case study Male, born in 1971, living with his parents, unfinished highschool, unemployed (precarious) 1991: started iv heroin 1999: entered OST programme (methadone 120 ml qid) tested anti-hcv positive, HCV RNA positive vaccinated for hepatitis B motivated for referral to infectologist refuses NO HEALTH PROBLEMS 2001: refered to infectologist (still in OST programme) mild fatigue HCV: GT3, ALT 3xUNL, IU/mL HCV RNA, liver US normal liver biopsy suggested refuses further referals NO HEALTH PROBLEMS; does not want liver biopsy 2004: referred to infectologist (still in OST programme) fatigue HCV: ALT 2xUNL, IU/mL HCV RNA PegIFN/RBV suggested (without liver biopsy) refuses further referals I have NO health problems! Do NOT want treatment side-effects!
43 A Case study 2006: refered to infectologist (in detoxication programme) moderate fatigue HCV: ALT nearly normal, IU/mL HCV RNA, US slightly enlarged liver PegIFN/RIBA suggested refuses further referals 2011: referred to infectologist (in prison; still in OST programme) extreme fatigue HCV: ALT nearly normal, 1.6 mill. IU/mL HCV RNA, US slightly enlarged liver suggested PegIFN/RBV without liver biopsy refuses further referals NO HEALTH PROBLEMS ; does not want to have treatment side effects!; does not want to have treatment during inprisonment (stigmatisation!) 2015: out of prison; still in OST programme information on DAA tretament option, additional motivation - refuses referals to inf. I have NO health problems! Do NOT want treatment side effects! 2016:still managed in OST programme (Methadone 100 ml qd) Fibroscan inside OST programme (Octobre)
44 A Case study 2006: referred to infectologist (in detoxication programme) moderate fatigue HCV: ALT nearly normal, IU/mL HCV RNA, US slightly enlarged liver PegIFN/RIBA suggested refuses further referals NO HEALTH PROBLEMS ; does not want to have treatment side effects! 2011: referred to infectologist (in prison; still in OST programme) extreme fatigue HCV: ALT nearly normal, 1.6 mill. IU/mL HCV RNA, US slightly enlarged liver PegIFN/RBV suggested without liver biopsy refuses further referals 2015: out of prison; still in OST programme information on DAA tretament option, additional motivation - refuses referals to inf. 2016:still managed in OST programme (Methadone 100 ml qd) Fibroscan inside OST programme (Octobre) Again: NO health problems! Do NOT want treatment side effects and STIGMATISATION!
45 A Case study 2006: referred to infectologist (in detoxication programme) moderate fatigue HCV: ALT nearly normal, IU/mL HCV RNA, US slightly enlarged liver PegIFN/RIBA suggested refuses further referals NO HEALTH PROBLEMS ; does not want to have treatment side effects! 2011: referred to infectologist (in prison; still in OST programme) extreme fatigue HCV: ALT nearly normal, 1.6 mill. IU/mL HCV RNA, US slightly enlarged liver PegIFN/RBV suggested without liver biopsy refuses further referals NO HEALTH PROBLEMS ; does not want to have treatment side effects!; does not want to have treatment during inprisonment (stigmatisation!) 2015: out of prison; still in OST programme information on DAA tretament option, additional motivation refuses referals to infectologist Again: NO health problems!
46 SLOVENIA Network of Centres for Prevention and Treatment of Drug Addiction Transient elastography introduced in 2016 A transportable Fibroscan - elastography performed in 18 Centers Klesnik M et al. INHSU 2017, New York, September 5-8,2017. Abstract #76.
47 A Case study 2016: still managed in OST programme (methadone 100 ml qd) severe fatigue Fibroscan offered within OST programme (October) OK, I will do it
48 A Case study Explanation of the transient elastography result 54.2 kpa
49 Patient reaction after understanding transient elastography result Drug treatment centre Counselling to prevent HCV infection Testing for HCV infection (every 6 12 months) HBV/HAV vaccination Identification of HCV treatment eligible patients Transient elastography on the spot (Fibroscan ) Motivation, assessment Linkage-to-care 54.2 kpa Viral hepatitis centre Medical evaluation/assessment Clinical management Counselling, motivation Treatment (DAAs) Matičič M, Kastelic A. Zdrav Vestn 2009;78:
50 A Case study October 2016: immediatelly refered to infectologist still severe fatigue ALT nearly normal, HCV RNA IU/mL, AFP negative US: slightly enlarged liver,hiperechogene parenchima, no round lesions Diagnosis: Compensated liver cirrhosis (Child-Pugh A) Co-medications: methadone (no DDI) EXTREMELY MOTIVATED for DAA treatment!!!!! October 2016: introduction of DAAs (sofosbuvir/velpatasvir + RBV, 12 weeks) November 2016 (w4): HCV RNA 57 IU/mL; No treatment AEs January 2017 (w12): HCV RNA negative treatment termination, ETR April 2017 (FU12): HCV RNA negative, AFP negative, US no pathological lesions in liver July 2017 (FU24): HCV RNA negative (SVR24) CURED Refered for FU visits every 6 months (US, AFP)
51 A Case study October 2016: immediatelly refered to infectologist still severe fatigue ALT nearly normal, HCV RNA IU/mL, AFP negative US: slightly enlarged liver,hiperechogene parenchima, no round lesions Diagnosis: Compensated liver cirrhosis (Child-Pugh A) Co-medications: methadone (no DDI) EXTREMELY MOTIVATED for DAA treatment!!!!! October 2016: introduction of DAAs (sofosbuvir/velpatasvir + RBV, 12 weeks) November 2016 (w4): HCV RNA 57 IU/mL; No treatment AEs January 2017 (w12): HCV RNA negative treatment termination, ETR April 2017 (FU12): HCV RNA negative, AFP negative, US no pathological lesions in liver July 2017 (FU24): HCV RNA negative (SVR24) CURED
52 A Case study Did the story end??? July 2018 (FU70): excellent phisical&psichological condition ALT normal, HCV RNA negative, AFP negative US: slightly enlarged liver, hiperechogene parenchima, two round lesions most probably HCC
53 A Case study Did the story end??? NO! Fibrosis stage F4: July 2018 (FU70): excellent phisical&psichological condition needs to have FU visits every 6 months (US, AFP) ALT normal, HCV RNA negative, AFP negative US: slightly enlarged liver, hiperechogene parenchima, two round lesions most probably HCC
54 A Case study January 2018 (FU 48): excellent phisical&psichological condition permanently employed new 28-y old female partner (HCV negative) lives in partner, s appartment attends an IT course (at age of 46) planning to have a child ALT normal, HCV RNA negative, AFP negative US: slightly enlarged liver, hiperechogene parenchima, no round lesions
55 A Case study January 2018 (FU 48): excellent phisical&psichological condition permanently employed new 28-y old female partner (HCV negative) lives in partner, s appartment attends an IT course (at age of 46) planning to have a child ALT normal, HCV RNA negative, AFP negative US: slightly enlarged liver, hiperechogene parenchima, no round lesions July 2018 (FU70): excellent phisical&psichological condition ALT normal, HCV RNA negative, AFP negative US: slightly enlarged liver, hiperechogene parenchima, two round lesions Hepatocellular carcinoma
56 What have we learnt from this case study In spite of existing national network for the management of HCV in PWUD that generally yields excellent results, an individual approach is needed to motivate HCV-positive PWUD for linkage-to-care and DAA treatment Results of transient elastograpy, made within OST centers and explained properly may present and excellent motivation for further linkage-to-care and HCV treatment Already existing local facilities and human potenial for diagnosing, linkage-to-care and treatment should be explored and used in an interdisciplinary way
57 Traditional referral model for HCV testing and treatment Modified from Jphn Dillon. INHSU, September 2018.
58 Redefining models of HCV testing and linkage-to-care Bring HCV care to the community where patients simply access services Modified from Jphn Dillon. INHSU, September 2018.
59 The long journey to HCV diagnosis Simplification is needed! Grebely J et al. Exp Rev Mol Diag 2017.
60 Rapid diagnostic tests needed Point-of-care HCV RNA test: one sep closer to a single-visit diagnosis needs to be more rapid! Real-world performances of HCV RNA quantification: - venepuncture: sensitivity 99%, speificity 96% - modified finger-stick assay: sensitivity 98%, specificity 99% - Xpert HCV VL Fingerstick: sensitivity 100%, specificity 100% McHigh J et al. J Clin Micro Grebely J et al. Lancet Gasro Hep Lamcuroury B et al. J Infect Dis 2018.
61 Simplification of models of care and interventions to access HCV testing and treatment Settings Services Providers Primary healthcare Drug/alcohol clinics N/S programe services STD clinics Pharmacies Community health services Prisons Rapid diagnostic tests Dried blood spot tests Point of care tests Fibroscan One pill a day Specialists General practitioners Addiction therapists Nurses Pharmacists Peers Others Greenman J, et al. J Viral Hepat 2015;22:353 61; Tuaillon E, et al. Hepatology 2010;51: Bruggman P, Litwin A. Clin Infect Dis 2013;57 (Suppl 2):S56 61; Alavi M, et al. Clin Infect Dis 2014; 57(Suppl2): S62 9; Seidenberg A, et al. BMC Inf Dis 2013; 13: 9; Butler K, et al. J Subst Abuse Treatment 2015;58:90 4; Brunner N, et al. INHSU 2015, Poster #008; Basanta JJA, et al. J Hepatol 2013; 58(Suppl 1):S321.; Dillon JF, et al. HMAP 2016; 1: Grebely J et al. Exp Rev Mol Diag 2017.
62 Simplification of existing models of care to access HCV treatment This is all that we need!!! Modified from Jphn Dillon
63 A TAKE-HOME MESSAGE One size will not fit all We need multiple models and interventions adapted to specific settings
A national multidisciplinary healthcare network for treatment of hepatitis C in PWID in Slovenia Prof. Mojca Matičič, MD, PhD
A national multidisciplinary healthcare network for treatment of hepatitis C in PWID in Slovenia Prof. Mojca Matičič, MD, PhD Clinic for Infectious Diseases and Febrile Illnesses University Medical Centre
More informationDAA Therapy and Reinfection Among People who Inject Drugs: Forming a Foundation for HCV Elimination
DAA Therapy and Reinfection Among People who Inject Drugs: Forming a Foundation for HCV Elimination Associate Professor Jason Grebely HEP DART 2017, Kohala Coast, Hawaii, 3 rd December 2017 Disclosures
More informationModels of care for management of HCV among PWID. Philip Bruggmann Switzerland
Models of care for management of HCV among PWID Philip Bruggmann Switzerland Disclosures Speaker and advisory board fees from Merck, Abbvie, Gilead, Janssen and BMS Financial support for projects of Arud
More informationHCV screening in Australia What we do now, and what we hope to do in future? Professor Gregory Dore
HCV screening in Australia What we do now, and what we hope to do in future? Professor Gregory Dore Disclosures Research grants, travel support, and honoraria: AbbVie, Gilead, Merck HCV screening in Australia
More informationWe know DAAs work for PWID, now what? Simplifying HCV testing, linkage to care and treatment
We know DAAs work for PWID, now what? Simplifying HCV testing, linkage to care and treatment Associate Professor Jason Grebely National Drug & Alcohol Research Centre, Sydney, Australia, 17 th May 2018
More informationFelice Nava, MD, PhD Felice A. Nava, MD PhD
Felice Nava, MD, PhD Felice A. Nava, MD PhD Direttore U.O. Sanità Penitenziaria Azienda ULSS 6 Euganea Padova Direttore Comitato Scientifico Nazionale FeDerSerD HCV 0? Dall Eradicazione del virus alla
More informationRECOMMENDATION FOR THE MANAGEMENT OF HEPATITIS C VIRUS INFECTION AMONG PEOPLE WHO INJECT DRUGS
RECOMMENDATION FOR THE MANAGEMENT OF HEPATITIS C VIRUS INFECTION AMONG PEOPLE WHO INJECT DRUGS The International Network on Hepatitis in Substance users (INHSU) Olav Dalgard Oslo Grebely J et al Int J
More informationSetting the Stage Key Challenges in Elimination
Setting the Stage Key Challenges in Elimination Jordan J. Feld MD MPH Toronto Centre for Liver Disease Sandra Rotman Centre for Global Health University of Toronto Disclosures Consulting: Abbvie, Contravir,
More informationUpdate in hepatitis C virus infection
Update in hepatitis C virus infection Eoin Feeney Consultant in Infectious Diseases St. Vincent s University Hospital Overview Natural history Diagnosis, screening, staging Management Barriers going forward
More informationHIV and HCV coinfection - Barriers in Central and Eastern Europe
HIV and HCV coinfection - Barriers in Central and Eastern Europe Jerzy Jaroszewicz Vice President of Polish Association for the Study of Liver Department of Infectious Diseases and Hepatology, Medical
More informationBruce Kreter, PharmD Senior Director, Global HCV Medical Affairs Gilead Sciences, Inc.
CDC Foundation & Viral Hepatitis Action Coalition: Summit for the Elimination of Hepatitis B and Hepatitis C as Public Health Threats in the United States Bruce Kreter, PharmD Senior Director, Global HCV
More informationARISTOTLE HCV-HIV: A fast-track intervention to seek-test-link-treat PWID in Athens, Greece
IVHEM, 6-7 December 2018 ARISTOTLE HCV-HIV: A fast-track intervention to seek-test-link-treat PWID in Athens, Greece Vana Sypsa Department of Hygiene, Epidemiology and Medical Statistics Medical School,
More informationEmerging epidemics: Will they derail progress? Eastern/Central Europe
Emerging epidemics: Will they derail progress? Eastern/Central Europe Marieta Simonova, MD Clinic of Gastroenterology, Military Medical Academy Sofia, Bulgaria Disclosures Speaker/Adviser for AbbVie, Gilead,
More informationHepatitis C. Request a Test. Benefits of testing in AOD services to improve treatment uptake
Hepatitis C Request a Test Benefits of testing in AOD services to improve treatment uptake Jenny Bourke Clinical Nurse Specialist Hepatitis C Community Clinic Christchurch About Hepatitis C Hepatitis is
More informationLa dernière frontière : simplification et intégration des soins
Jean-Michel Delile CEID, Bordeaux Vice-président de la Fédération Addiction jm.delile@ceid-addiction.com ATHS Biarritz, 18/10/2017 Atelier «Simplifier pour éliminer l hépatite C» La dernière frontière
More informationHepatitis C Elimination Program Georgia
Hepatitis C Elimination Program Georgia Maia Butsashvili, MD, MS, PhD Health Research Union (HRU)/Clinic NEOLAB National HCV Committee International School of Public Health High prevalence of HCV in Georgia
More informationHEPATITIS B: WHO AND WHEN TO TREAT?
HEPATITIS B: WHO AND WHEN TO TREAT? George V. Papatheodoridis Professor in Medicine & Gastroenterology Medical School of National & Kapodistrian University of Athens Director of Academic Department of
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Clinical Criteria for Hepatitis C (HCV) Therapy Pre-Treatment Evaluation o Must have chronic hepatitis C and HCV genotype and sub-genotype documented; o Patients who have prior exposure to DAA therapy
More informationHepatitis C Virus (HCV) & Infectious Disease 101 for Hubs & Spokes April 24, :00 pm 1:00 pm
Hepatitis C Virus (HCV) & Infectious Disease 101 for Hubs & Spokes April 24, 2018 12:00 pm 1:00 pm Presenters: Thomas E. Freese, PhD, Larissa Mooney, MD, & Rachel McLean, MPH, Chief, Office of Viral Hepatitis
More informationHIV/Sexual Health Clinical Education Session.
HIV/Sexual Health Clinical Education Session http://courses.ashm.org.au/hiv/hiv-sexual-health-clinical-education-session/ About These Slide These slides may not be published, posted online, or used in
More informationWill HCV therapies deliver global impact? Professor Greg Dore
Will HCV therapies deliver global impact? Professor Greg Dore Disclosures Gregory Dore has received research grants awarded to his institution from Gilead, Bristol Myers Squibb, Abbvie, Merck, and Janssen;
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Clinical Criteria for Hepatitis C (HCV) Therapy Pre-Treatment Evaluation o Must have chronic hepatitis C and HCV genotype and sub-genotype documented; o Patients who have prior exposure to DAA therapy
More informationSection 7: Providing HCV testing and treatment to people who inject drugs
Section 7: Providing HCV testing and treatment to people who inject drugs Dr. Niklas Luhmann (Médecins du Monde) Training Hepatitis C and HR for PWUD, 9 th -13 th May 2016, Hanoi, Vietnam Learning objective
More informationTreatment of Hepatitis C in People Who Inject Drugs (PWIDs) Andrew Seaman, MD OHA P&T Meeting January, 2017
Treatment of Hepatitis C in People Who Inject Drugs (PWIDs) Andrew Seaman, MD OHA P&T Meeting January, 2017 Conflicts of interest Receive
More informationHepatitis C Elimination: Australia s progress
Hepatitis C Elimination: Australia s progress Margaret Hellard Burnet Institute, Melbourne Disclosures I receive fellowship support from the National Health and Medical Research Council (Australia). The
More informationHCV elimination : lessons from Scotland
HCV elimination : lessons from Scotland Sharon Hutchinson Glasgow Caledonian University / Health Protection Scotland BHIVA Hepatology Highlights, Edinburgh, 17 th April 2018 Disclosures Honoraria from
More information7th International Symposium on Hepatitis Care in Substance Users
7th International Symposium on Hepatitis Care in Substance Users The Abstract Guidelines must be followed as closely as possible in order for your presentation to be considered. Please ensure that the
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Clinical Criteria for Hepatitis C (HCV) Therapy Pre-Treatment Evaluation o Must have chronic hepatitis C and HCV genotype and sub-genotype documented; o Patients who have prior exposure to DAA therapy
More informationHCV: how do we reach elimination from a clinicians perspective. A/Professor Gail Matthews
HCV: how do we reach elimination from a clinicians perspective A/Professor Gail Matthews WHO global hepatitis elimination goals by 2030 Elimination a reduction in HCV incidence and HCVrelated mortality
More information29/09/2014. Expanding access to hepatitis C treatment through primary care: Challenges and opportunities. Disclosures
2013 Viremic Cases 29/09/2014 Expanding access to hepatitis C treatment through primary care: Challenges and opportunities Professor Greg Dore Kirby Institute, UNSW Australia; & St Vincent s Hospital,
More informationHepatitis C Strategy. About us. What is hepatitis C?
Hepatitis C Strategy About us We support people to take control of their lives and make positive changes. For fifty years we have made a difference to people who want to change their relationship with
More informationThe Changing World of Hepatitis C
The Changing World of Hepatitis C Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia St. Paul s Hospital Site Disclosures
More informationEfficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: The SIMPLIFY study
Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: The SIMPLIFY study Olav Dalgard Professor dr med Akershus University Hospital
More informationTargeted Outreach & Other Strategies for Increasing HCV Testing
Targeted Outreach & Other Strategies for Increasing HCV Testing Working in Settings that Serve High-Risk Populations Webcast 2.4 Presented By: Denise Stinson, MN, RN Tacoma-Pierce County Health Department
More informationHIV, HBV and HCV testing policy experiences and lessons learned.
HIV, HBV and HCV testing policy experiences and lessons learned. Contents HIV and viral hepatitis: distinct epidemics at different stages of evolution Epidemiology: transmission, prevalence, incidence
More informationToronto Declaration: Strategies to control and eliminate viral hepatitis globally. A call for coordinated action
Toronto Declaration: Strategies to control and eliminate viral hepatitis globally A call for coordinated action Hepatitis B National Action Plan All countries should develop a national and/or regional
More informationHCV therapy : Clinical case
HCV therapy : Clinical case PHC 2018 Paris January 14th, 2018 Tarik Asselah (MD, PhD) Professor of Medicine Hepatology, Chief INSERM UMR 1149, Hôpital Beaujon, Clichy, France. Disclosures Professor Asselah
More informationToronto Declaration 2014: Global Strategies to control and eliminate viral hepatitis globally. A call for coordinated action
Toronto Declaration 2014: Global Strategies to control and eliminate viral hepatitis globally A call for coordinated action Disclaimer Toronto declaration is not aiming to reinvent the wheel or interfere
More informationWelcome to A Chronic Disease You Can Cure: Hepatitis C Treatment for Primary Care Providers Conference February 24, 2018
Welcome to A Chronic Disease You Can Cure: Hepatitis C Treatment for Primary Care Providers Conference February 24, 2018 Approved Provider Statements: ANTHC is accredited by the Washington State Medical
More informationProfessor Mark Nelson. Chelsea and Westminster Hospital, London, UK
Professor Mark Nelson Chelsea and Westminster Hospital, London, UK Treatment should be prioritized Treatment Indicated All naive and experienced pts with liver disease Prioritized Pts with fibrosis (F3)
More informationHepatitis C Virus (HCV): Current Screening Guidelines and Treatment Approaches
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/medical-breakthroughs-from-penn-medicine/hepatitis-c-virus-hcvcurrent-screening-guidelines-treatment-approaches/9514/
More informationHCV care after cure. This program is supported by educational grants from
HCV care after cure This program is supported by educational grants from Raffaele Bruno,MD Department of Infectious Diseases, Hepatology Outpatients Unit University of Pavia Fondazione IRCCS Policlinico
More informationDeveloping the campaign
Liver Disease Burden and Clinical Follow-Up During a Liver Health Promotion Intervention Integrating Non-Invasive Liver Disease Screening in Drug and Alcohol Settings: The LiveRLife Study Grebely J 1,
More informationHepatitis Alert: Management of Patients With HCV Who Have Achieved SVR
Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR This program is supported by educational grants from AbbVie, Gilead Sciences, and Merck About These Slides Please feel free to use,
More informationCURING HEPATITIS C IN GENERAL PRACTICE: THE FIRST 60 DAYS
CURING HEPATITIS C IN GENERAL PRACTICE: THE FIRST 60 DAYS Baker D 1,2, McMurchie M 1, Rodgers C 1, Farr V 1, Williams M 1 1 East Sydney Doctors, 2 Australasian Society for HIV Medicine 1 Disclosures Advisory
More informationHow to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France
How to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France Paris Hepatitis Conference, January 12, 2016 Disclosures I have received funding
More informationCivil Society Driven Response in Ukraine: A program making a difference and bringing results
Civil Society Driven Response in Ukraine: A program making a difference and bringing results CATIE Forum Making it work: From Planning to Practice October 16th, 2015 Andriy Klepikov International HIV/AIDS
More informationHepatitis C in Disclosures
Hepatitis C in 2018 Sandeep Mukherjee, MD CHI Health and Creighton University Medical Center Division of Gastroenterology Grant support: Abbvie Disclosures Speaker: Abbvie, Gilead, Merck Section editor
More informationHepatitis C Virus Diagnostics: The Road to Simplification
Hepatitis C Virus Diagnostics: The Road to Simplification Jordan J. Feld, M.D., M.P.H. The ambitious goal of eliminating viral hepatitis as a public health problem by 2030 will require major efforts to
More informationIntegrating Hepatitis C into Drug Treatment Settings
Integrating Hepatitis C into Drug Treatment Settings Substance Use Disorders Statewide Conference August 24, 2017 Pomona, CA Christine Rodriguez, MPH California Department of Public Health 1. Hepatitis
More informationDr David Rowbotham NHS. The Leeds Teaching Hospitals. NHS Trust
Dr David Rowbotham The Leeds Teaching Hospitals NHS Trust NHS Nurses Update June 2010 Chronic Hepatitis HBV / HCV David Rowbotham Clinical Director & Consultant Gastroenterologist Dept of Gastroenterology
More informationHepatitis C Infection: Updated Information for Front Line Workers in Primary Care Settings MAMTA K. JAIN, MD, MPH 2/14/18
Hepatitis C Infection: Updated Information for Front Line Workers in Primary Care Settings MAMTA K. JAIN, MD, MPH 2/14/18 Overview Hepatitis C Virus Prevalence Effects of Hepatitis C Prevention Diagnosis
More informationWorldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC Mark W. Russo, MD, MPH, FACG Carolinas HealthCare System Charlotte Worldwide Causes of HCC 60% 50% 40% 30% 20% 10% 0% 54% 31% 15% Hepatitis B Hepatitis C
More informationEpidemiology of Pathogenesis of HCV A Focus on HIV
Epidemiology of Pathogenesis of HCV A Focus on HIV Presented by MayaTech in conjunction with Dr. Camilla Graham, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA Our Speaker Dr.
More informationHepatitis C The NHS Model. Professor Graham R Foster Professor of Hepatology Barts Liver Centre QMUL
Hepatitis C The NHS Model Professor Graham R Foster Professor of Hepatology Barts Liver Centre QMUL The NHS Approach Background The strategy Tactics The NHS Approach Background The strategy Tactics NHSE
More informationHepatitis C Management and Treatment
Hepatitis C Management and Treatment Kaya Süer Near East University Faculty of Medicine Infectious Diseases and Clinical Microbiology 1 Discovery of Hepatitis C Key facts Hepatitis C: the virus can cause
More informationTetiana Kyrychenko MD. Poltava Regional HIV/AIDS Prevention and Control Center. 4TH CEE MEETING ON VIRAL HEPATITIS AND HIV October 2018, Prague
Tetiana Kyrychenko MD Poltava Regional HIV/AIDS Prevention and Control Center 4TH CEE MEETING ON VIRAL HEPATITIS AND HIV 11-12 October 2018, Prague tanakyrychenko@gmail.com Disclosures No relevant conflicts
More informationImpatto della clearance virale e rischio di carcinoma epatocellulare
EPATITE CRONICA DA HCV: Impatto della clearance virale e rischio di carcinoma epatocellulare Rodolfo Sacco, M.D., PhD Direttore U.O.C. Gastroenterologia ed Endoscopia Digestiva A.O.U. Ospedali Riuniti"
More informationWHO Strategy and Goals for Viral Hepatitis Elimination
WHO Strategy and Goals for Viral Hepatitis Elimination No Disclosures Outline 1. Global strategy for elimination WHO targets and rationale 2. The global response so far Gaps in achieving the HBV and HCV
More informationStrategies to Enhance the Hepatitis C Care Cascade Among People Who Inject Drugs
Strategies to Enhance the Hepatitis C Care Cascade Among People Who Inject Drugs Jason Grebely, PhD Associate Professor Viral Hepatitis Clinical Research Program The Kirby Institute UNSW Australia Disclosures
More informationIFN IFN IFN/RBV IFN/RBV
Medicaid and Viral Hepatitis Treatment in Kentucky Kentucky 5th Annual Viral Hepatitis Conference Ending the Epidemic: The Role of Professionals in Hepatitis Elimination Disclosure Jens Rosenau has received
More informationSpecial developments in the management of Hepatitis C. Disclosures
Special developments in the management of Hepatitis C Sandeep Mukherjee,MD Division of Gastroenterology CHI Health and Creighton University Medical Center Omaha, NE 68154 Sandeep.Mukherjee@alegent.org
More informationHepatitis B: A Preventable Cause of Liver Cancer. Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016
Hepatitis B: A Preventable Cause of Liver Cancer Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016 Overview Epidemiology HBV and cancer Screening, Diagnosis
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline Name Sovaldi (sofosbuvir) Formulary UnitedHealthcare Community & State Formulary Note Approval Date 2/19/2014 Revision Date 7/8/2014 1. Indications Drug Name: Sovaldi
More informationUpdate on Hepatitis B and Hepatitis C
Update on Hepatitis B and Hepatitis C Catherine Stedman Department of Gastroenterology, Christchurch Hospital and University of Otago, Christchurch Disclosures I have the following financial relationships
More informationStrategies to enhance HCV testing, linkage to care and treatment
Strategies to enhance HCV testing, linkage to care and treatment STACEY B. TROOSKIN M D PHD DIREC TOR OF VIRAL HEPAT I T IS PROGRAMS PHILADELPHIA FIGHT COMMUNITY HEA LT H CENTERS PHILADELPHIA, PA Disclosures
More informationHepatitis C in Correctional Facilities: Big Problem, Bigger Opportunity. Cody A. Chastain, MD
Hepatitis C in Correctional Facilities: Big Problem, Bigger Opportunity Cody A. Chastain, MD Disclosures Research supported by Gilead Sciences Inc.: Site investigator for HIV/HCV SWITCH Registry Study
More informationHow to prioritise HCV treatment
How to prioritise HCV treatment From the perspective of the medical community Margaret Hellard Declarations NHMRC fellowship Burnet receives infrastructure support from the Victorian Government Gilead
More informationUniversal HCV treatment: Strategies for simplification
Universal HCV treatment: Strategies for simplification PARIS HEPATOLOGY CONFERENCE 3 January 217 Tarik Asselah (MD, PhD) Hepatology & Chief INSERM UMR 1149, Hôpital Beaujon, Clichy, France. Disclosures
More informationCatalyst for Change. Viral Hepatitis Control Program Country Model Ukraine. Zahedul Islam
Catalyst for Change Viral Hepatitis Control Program Country Model Ukraine Zahedul Islam Director: Treatment, Procurement & Supply Alliance for Public Health Ukraine Alliance for Public Health Alliance
More informationHEPATITIS C. Whitney Dickson, PharmD, BCPS October 12 th, 2017
HEPATITIS C Whitney Dickson, PharmD, BCPS October 12 th, 2017 MY BACKGROUND Pharmacy School: University of California San Diego Pharmacy Practice Residency (PGY1): University of Illinois at Chicago HIV/Hep
More informationGlobal reporting system for hepatitis (GRSH) project description
Global reporting system for hepatitis (GRSH) project description Contents 1. Background... 2 2. Target audience for this document... 2 3. Data to be reported through the Global Reporting System for Hepatitis...
More informationPHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline
PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline Preferred Regimen Based on Diagnosis: Mavyret (glecaprevir/pibrentasvir ) Non-Preferred: Daklinza (daclatasvir) Epclusa (sofosbuvir/velpatasvir)
More informationEliminating Hepatitis C by 2030 Enhancing Prevention, Care and Treatment Among People who Inject Drugs
Eliminating Hepatitis C by 2030 Enhancing Prevention, Care and Treatment Among People who Inject Drugs Professor Margaret Hellard Disclosures I receive fellowship support from the National Health and Medical
More information4th International HIV/Viral Hepatitis Co- Infection Meeting
INSTITUTIONAL STRAPLINE 4th International HIV/Viral Hepatitis Co- Infection Meeting The Rocky Road to Viral Hepatitis Elimination: Approaches for simplified HCV diagnostics and screening algorithms: thoughts
More informationNational Hepatitis C Elimination Program of Georgia
European Roundtable on Hepatitis Cure & Eradication 2015 9-10 September 2015, Frankfurt, Germany National Hepatitis C Elimination Program of Georgia Tengiz Tsertsvadze MD, PhD Director General Infectious
More informationPretreatment Evaluation
Pretreatment Evaluation Disclosures Research supported by Gilead Sciences Inc.: Site investigator for HIV/HCV SWITCH Registry Study Key personnel for FOCUS HCV Screening Program through Vanderbilt University
More informationPrimary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O.
Primary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O. Objectives Epidemiology of chronic hepatitis C CDC guidelines on screening or hepatitis C Diagnosing hepatitis
More informationHepatitis C epidemiology, screening and treatment
Hepatitis C epidemiology, screening and treatment Date Presenter Wednesday 29 August 2018: 7.00-8.00pm Professor Greg Dore This education activity has been developed in association with: Kirby Institute,
More informationPennsylvania Academy of Family Physicians Foundation & UPMC 43rd Refresher Course in Family Medicine CME Conference March 10 13, 2016
Pennsylvania Academy of Family Physicians Foundation & UPMC 43rd Refresher Course in Family Medicine CME Conference March 10 13, 2016 Disclosures: Hep C Update N. Randy Kolb, MD Speakers has received Funding
More informationEliminating Hepatitis C from New Zealand
Eliminating Hepatitis C from New Zealand Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital Disclosures I have the following
More informationModels of HCV screening & treatment: An evidence-based international perspective
Scottish University of the Year 2017 Models of HCV screening & treatment: An evidence-based international perspective Prof John F Dillon Page 1 Declaration of Financial Interests or Relationships Speaker
More informationUpdate on Hepatitis C. Francesco Negro Hôpitaux Universitaires de Genève Berne, November 15, 2017
Update on Hepatitis C Francesco Negro Hôpitaux Universitaires de Genève Berne, November 15, 2017 The global prevalence of HCV was 1 0% (95% uncertainty interval 0 8 1 1) in 2015: 71 1 million (62 5 79
More informationModule 1 Introduction of hepatitis
Module 1 Introduction of hepatitis 1 Training Objectives At the end of the module, trainees will be able to ; Demonstrate improved knowledge of the global epidemiology of the viral hepatitis Understand
More informationLength of Authorization: 8-12 weeks. Requires PA: All direct-acting antivirals for treatment of Hepatitis C. Approval Criteria
Hepatitis C Direct-Acting Antivirals Goals: Approve use of cost-effective treatments supported by the medical evidence. Provide consistent patient evaluations across all hepatitis C treatments. Ensure
More informationNon-Invasive Testing for Liver Fibrosis
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Non-Invasive Testing for Liver Fibrosis John Scott, MD, MSc Associate Professor, University of Washington Associate Clinic Director, Hep/Liver Clinic, Harborview
More informationNational Hepatitis plan. Dr JP Mulkay Clinic of Hepatology Department of Hepato Gastro entrology
National Hepatitis plan Dr JP Mulkay Clinic of Hepatology Department of Hepato Gastro entrology National hepatitis Plan Hepatitis B: plan non existent. People s migration from endemic countries. Reimbursement
More informationWhy make this statement?
HCV Council 2014 10 clinical practice statements were evaluated by the Council A review of the available literature was conducted The level of support and level of evidence for the statements were discussed
More informationBarriers to Management of HCV: Treating People Who Use Drugs. May 9, 2015
Barriers to Management of HCV: Treating People Who Use Drugs Alain Litwin, MD, MPH Albert Einstein College of Medicine Montefiore Medical Center May 9, 2015 Disclosures Gilead Pharmaceuticals Janssen Pharmaceuticals
More informationOvercoming Barriers to Hepatitis C Treatment Among Substance Users
Overcoming Barriers to Hepatitis C Treatment Among Substance Users Marija Zeremski, PhD Project Director Clinical Directors Network, Inc. (CDN) Monday, October 2, 2017 1 PM 2:30 PM EST 1 Overview and Learning
More informationHepatitis C Direct-Acting Antivirals
Hepatitis C Direct-Acting Antivirals Goals: Approve use of cost-effective treatments supported by the medical evidence. Provide consistent patient evaluations across all hepatitis C treatments. Ensure
More informationShorter Durations and Pan-genotypic Regimens The Final Frontier. Professor Greg Dore
Shorter Durations and Pan-genotypic Regimens The Final Frontier Professor Greg Dore Disclosures Funding and speaker fees from AbbVie, Bristol-Myers Squibb, Gilead Sciences and Merck Efficacy Evolution
More informationTHE THERAPEUTIC REVOLUTION THAT TRANSFORMED CHRONIC HEPATITIS C TO A CURABLE DISEASE
THE THERAPEUTIC REVOLUTION THAT TRANSFORMED CHRONIC HEPATITIS C TO A CURABLE DISEASE MARIA SCHINA CONSULTANT PHYSICIAN INTERNAL MEDICINE AND HEPATOLOGY ATHENS EUROCLINIC 10 th INTERNATIONAL CONGRESS OF
More informationHepatitis C. Core slides
Hepatitis C Core slides This material was prepared by the Viral Hepatitis Prevention Board The slides (or subsets) can be reproduced for educational use only, with reference to the original source and
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationHCV treatment in Australia: a new role for GPs
Disclosures HCV treatment in Australia: a new role for GPs Dr David Iser The Alfred & St. Vincent s Hospitals 15 th October 2016 I have received honoraria for presentations and/or consultancies from: AbbVie
More information2018 NYC. Viral Hepatitis Research Symposium
Implementation and Evaluation of a Care Coordination Intervention for Patients with HCV Following Release from the New York City Jails Matthew Akiyama, MD, MSc Montefiore Medical Center / Albert Einstein
More informationNew Exception Status Benefits
APRIL 2018 Nova Scotia Formulary Updates New Exception Status Benefits Lenvima Updates for Hepatitis C Medications Daklinza Epclusa Harvoni Sovaldi Zepatier New Diabetic Product New Ostomy Products Nova
More informationIntegrating hepatitis C treatment in a regional setting The Cairns Experience. DANA 2018 Morag Goodinson
Integrating hepatitis C treatment in a regional setting The Cairns Experience DANA 2018 Morag Goodinson I would like to acknowledge the Traditional Owners of the land, and pay respect to Elders past, present
More information